HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer{star, open}

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 3, 2006, Pages 207-215

  Rosato, Antonio ^a   Banzato, Alessandra ^a   De Luca, Gilda ^b   Renier, Davide ^b   Bettella, Fabio ^b   Pagano, Claudio ^a   Esposito, Giovanni ^a   Zanovello, Paola ^a   Bassi, PierFrancesco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Fidia Advanced Biopolymers   (Italy)

Author keywords

Biconjugate; Cancer treatment; Hyaluronic acid; Paclitaxel; Superficial bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIOMATERIAL; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; HYTAD1 P20; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BLADDER CANCER; BLADDER CARCINOMA; BLADDER MUCOSA; CANCER CELL CULTURE; CANCER GROWTH; CATHETERIZATION; CELL INFILTRATION; COMBINED IMMUNODEFICIENCY; CONJUGATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFECT; DRUG SOLUBILITY; DRUG TOLERABILITY; ESTERIFICATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TUMOR CELL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYALURONIC ACID; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, SCID; PACLITAXEL; TISSUE DISTRIBUTION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33646186702     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.08.020     Document Type: Article

References (30)

1. Borden Jr. L.S., Clark P.E., and Hall M.C. Bladder cancer. Curr Opin Oncol 16 (2004) 257-262
2. Dinney C.P., McConkey D.J., Millikan R.E., et al. Focus on bladder cancer. Cancer Cell 6 (2004) 111-116
3. Schenkman E., and Lamm D.L. Superficial bladder cancer therapy. Scientific WorldJournal 4 Suppl 1 (2004) 387-399
4. Kassouf W., and Kamat A.M. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4 (2004) 1037-1046
5. Crawford E.D. Intravesical therapy for superficial cancer. Need for more options. J Clin Oncol 20 (2002) 3185-3186
6. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
7. Cormio G., Di Vagno G., Melilli G.A., et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 11 (1999) 407-409
8. Weiss R.B., Donehower R.C., Wiernik P.H., et al. Hypersensitivity reactions from taxol. J Clin Oncol 8 (1990) 1263-1268
9. Nativ O., Aronson M., Medalia O., et al. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer. In vivo and in vitro studies. Int J Cancer 70 (1997) 297-301
10. Knemeyer I., Wientjes M.G., and Au J.L. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44 (1999) 241-248
11. Toole B.P. Hyaluronan. From extracellular glue to pericellular cue. Nat Rev Cancer 4 (2004) 528-539
12. Marhaba R., and Zoller M. CD44 in cancer progression. Adhesion, migration and growth regulation. J Mol Histol 35 (2004) 211-231
13. Nedvetzki S., Gonen E., Assayag N., et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice. A different interpretation of redundancy. Proc Natl Acad Sci U S A 101 (2004) 18081-18086
14. Weigel J.A., Raymond R.C., McGary C., et al. A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits hyaluronan clearance by perfused liver. J Biol Chem 278 (2003) 9808-9812
15. Kong Q.Y., Liu J., Chen X.Y., et al. Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep 10 (2003) 51-55
16. Lipponen P., Aaltoma S., Kosma V.M., et al. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 186 (1998) 157-164
17. Ross J.S., del Rosario A.D., Bui H.X., et al. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol 9 (1996) 854-860
18. Luo Y., Bernshaw N.J., Lu Z.R., et al. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res 19 (2002) 396-402
19. Luo Y., Ziebell M.R., and Prestwich G.D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 1 (2000) 208-218
20. Luo Y., and Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 10 (1999) 755-763
21. Li H., Liu Y., Shu X.Z., et al. Synthesis and biological evaluation of a cross-linked hyaluronan-mitomycin C hydrogel. Biomacromolecules 5 (2004) 895-902
22. Quintieri L., Rosato A., Napoli E., et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin. Role of cytochrome P450 3A. Cancer Res 60 (2000) 3232-3238
23. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Cancer Metastasis Rev 8 (1989) 82-88
24. Lu Z., Yeh T.K., Tsai M., et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 10 (2004) 7677-7684
25. Au J.L., Kalns J., Gan Y., et al. Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 41 (1997) 69-74
26. Suh H., Jeong B., Rathi R., et al. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J Biomed Mater Res 42 (1998) 331-338
27. Wang Y.M., Sato H., Adachi I., et al. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem Pharm Bull (Tokyo) 44 (1996) 1935-1940
28. Harper E., Dang W., Lapidus R.G., et al. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res 5 (1999) 4242-4248
29. Le Visage C., Rioux-Leclercq N., Haller M., et al. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 171 (2004) 1324-1329
30. Sandri G., Rossi S., Ferrari F., et al. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol 56 (2004) 1083-1090